Previous close | 28.10 |
Open | 28.10 |
Bid | 0.00 |
Ask | 0.00 |
Strike | 200.00 |
Expiry date | 2025-01-17 |
Day's range | 28.10 - 28.10 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Investor focus is likely to be on the sales of AbbVie's (ABBV) blockbuster immunology drugs Rinvoq and Skyrizi when it reports first-quarter results.
AbbVie stock has slumped 9% off its record high in March and is facing increasingly steep competition for its biggest moneymaker, Humira.
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.